<DOC>
	<DOCNO>NCT00346632</DOCNO>
	<brief_summary>Non-randomized , open , dose range dose scheduling study ascend dos KW-2449 subject AML , ALL , MDS CML .</brief_summary>
	<brief_title>An Ascending Dose Study KW-2449 Acute Leukemias , Myelodysplastic Syndromes , Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>This Phase I open-label dose escalation study KW-2449 subject acute leukemia , high risk MDS , CML candidate approve therapy . Over 18-month period , investigative site collectively enroll total 96 subject . Subjects enrol sequentially 1 7 dose group evaluate 2 dose schedule ( Arm A = 14 consecutive day dose follow 7-28 day rest period determine recovery acute hematologic non-hematologic toxicity , Arm B = 28 consecutive day dose follow 7-28 day rest period , determined recovery acute hematologic non-hematologic toxicity ) . The safety dose level Arm A ( 14-day dose regimen ) establish prior enrollment subject dose level Arm B ( 28-day dose regimen ) . In April 2007 protocol amend discontinue Arm B ( 28 consecutive day dose ) . The protocol continue plan Arm A ( 14 day consecutive dosing ) . Enrollment proceed maximum tolerate dose ( MTD ) establish study Arm . Once MTD reach , 12 additional subject , 1 hematologic condition include study , may enrol MTD expand safety cohort .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>1 . Histologically confirm diagnosis : AML ( include APL refractory alltrans retinoic acid arsenic ) relapse responsive prior chemotherapy ; Relapsed/refractory ALL ; CML fail respond lose response imatinib ; Advanced MDS ( INT2 High risk IPSS ) failure intolerance approve therapy . 2 . ECOG Performance Status score 0 , 1 , 2 ; 3 . Male female , least 18 year age ; 4 . Signed write informed consent ; 5 . Serum creatinine ≤ 2.0 mg/dL ; 6 . Serum SGOT ( AST ) SGPT ( ALT ) ≤ 5x ULN ; serum bilirubin ≤ 2 mg/dL ( serum bilirubin may ≤ 3.0 mg/dL subject Gilbert 's Syndrome ) ; 7 . For female childbearing potential , negative serum pregnancy test . Subjects , childbearing potential , must use Investigatorapproved method birth control . 1 . Candidates approve therapy ; 2 . Concomitant treatment investigational agent , chemotherapy , radiotherapy , immunotherapy ; 3 . Active CNS leukemia ; 4 . Previous concurrent malignancy except noninvasive nonmelanomatous skin cancer , situ carcinoma cervix , solid tumor treat curatively , without evidence recurrence least 2 year prior study entry ; 5 . Uncontrolled systemic infection ( viral , bacterial , fungal ) ; 6 . Uncontrollable disseminated intravascular coagulation ; 7 . Major surgery within 28 day precede first dose KW2449 ; 8 . Radiotherapy , lack recovery radiotherapyrelated acute toxicity , within 28 day precede first dose KW2449 ; 9 . Treatment systemic therapy underlie hematologic condition , lack recovery toxicity treatment , within 28 day first dose KW2449 , follow exception : hydroxyurea treatment hyperleukocytosis ( discontinue least 48 hour prior first dose KW2449 ) ; imatinib ( discontinue least 48 hour prior first dose KW2449 ) ; interferon ( discontinue least 7 day prior first dose KW2449 ) ; 10 . Treatment investigational agent , lack recovery toxicity treatment , within 28 day precede first dose KW2449 ; 11 . Positive serology HIV ; 12 . Clinically significant cardiac dysfunction ( New York Heart Association Class 3 4 ) time screen , history myocardial infarction heart failure within 3 month precede first dose KW2449 ; 13 . Any evidence chronic Graft versus Host Disease ; 14 . Active autoimmune disease require immunosuppressive therapy ; 15 . Female subject pregnant breast feeding ; 16 . Subjects childbearing potential , unwilling use approve , effective mean contraception accordance institution 's standard ; 17 . Known current drug alcohol abuse ; 18 . Other severe , acute , chronic medical psychiatric condition , laboratory abnormality may compromise safety subject study , affect subject 's ability complete study , interfere interpretation study result ; 19 . For reason judge Investigator inappropriate study participation , include inability communicate cooperate Investigator . 20 . Hematopoietic growth factor ( i.e. , erythropoietin darbepoetin alpha , filgrastim [ granulocyte colonystimulating factor { GCSF } ] , sargramostim [ granulocytemacrophage colonystimulating factor { GMCSF } ] , thrombopoietic agent ) corticosteroid within 14 day study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>ALL</keyword>
	<keyword>MDS</keyword>
	<keyword>CML</keyword>
	<keyword>Kinase Inhibitor</keyword>
</DOC>